Remove DEA Remove Medical Evaluation Remove Treatment
article thumbnail

Document: Barr Responses To QFR’s: CLR Digs Out The Relevant Q’s & A’s

Cannabis Law Report

To expand the number of manufacturers, the Drug Enforcement Administration (DEA) submitted a notice in the Federal Register on August 11, 2016, soliciting applications for licenses to manufacture marijuana for research purposes. However, over two years have passed without any new schedule I marijuana manufacturer registrations.

article thumbnail

Rescheduling Marijuana

Connor & Connor PLLC

Currently, marijuana is a Schedule I substance, meaning it is thought to have no medical value, a high probability of addiction, and a lack of any accepted safety or use in medically supervised treatment. On May 21, 2024, the DEA opened a 62-day public comment period, which concluded on July 22, 2024.